Cigarette Smoking and Protection from Parkinson's Disease:False Association or Etiologic Clue?
Neurol 45:1041-1051, Morens,D.M.,et al, 1995
Risk of Dementia After Initiation of Sodium-Glucose Cotransporter-2 Inhibitors Versus Dipeptidyl Peptidase-4 Inhibitors in Adults Aged 40-69 years with type 2 Diabetes:Population Based Cohort Study
BMJ doi:10.1136/BMJ-2024-07945, Shin,A., et al, 2024
SGLT2 Inhibitor Use and Risk of Dementia and Parkinson Disease Among Patients With Type 2 Diabetes
Neurol 103:e209805, Kim,H.K.,et al, 2024
NSAID Use and Dementia Risk in the Cardiovascular Health Study: Role of APOE and NSAID Type
Neurol 70:17-24, Szekely,C.A.,et al, 2008
Invited Article: Changing Concepts in Parkinson Disease: Moving Beyond the Decade of the Brain
Neurol 70:1996-2003, Marras,C. &Lang,A., 2008
Effect of Demebon on Cognition, Activities of Daily Living, Behavior, and Global Function in Patients With Mild-To-Moderate Alzheimers Disease: A Randomised, Double-Blind, Placebo-Controlled Study
Lancet 372:207-215,179, Doody, R.S.,et al., 2008
The Neuroprotective Effects of Caffeine: A Prospective Population Study (the Three City Study)
Neurol 69:536-545, Ritchie,K.,et al, 2007
Disease-Modifying Therapies for Alzheimer Disease: Challenges to Early Intervention
Neurol 69:1622-1634, Cummings,J.L.,et al, 2007
Antioxidant Vitamin Intake and Risk of Alzheimer Disease
Arch Neurol 60:203-208, Luchsinger,J.A.,et al, 2003
Evidence for Widespread Axonal Damage at the Earliest Clinical Stage of Multiple Sclerosis
Brain 126:433-437, Filippi,M.,et al, 2003
Reduced Incidence of AD with NSAID But Not H2 Receptor Antagonists
Neurol 59:880-886, Zandi,P.P.,et al, 2002
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
NEJM 345:1515-1521,1567, in 'T Veld,B.A.,et al, 2001
Reduced Prevalence of AD in Users of NSAIDs and H2 Receptor Antagonists
Neurol 54:2066-2071, Anthony,J.C.,et al, 2000
Nonsteroidal Anti-Inflammatory Drug use and Alzheimer-Type Pathology in Aging
Neurol 50:986-990, Mackenzie,I.&Munoz,D.G., 1998
Estrogen-replacement Therapy and Alzheimer's disease in the Italian Longitudinal Study on Aging
Neurol 50:996-1002, Baldereschi,M.,et al, 1998
Risk of Alzheimer's Disease and Duration of NSAID Use
Neurol 48:626-632, Stewart,W.F.,et al, 1997
Characterizing the Target of Acute Stroke Therapy
Stroke 28:866-872, Fisher,M., 1997
A Prospective Study of Estrogen Replacement Therapy and the Risk of Developing Alzheimer's Disease
Neurol 48:1517-1521, Kawas,C.,et al, 1997
A 60-Year-Old Man with Parkinson's Disease
JAMA 275:716-722, Olanow,C.W., 1996
Dietary Flavonoids, Antioxidant Vitamins, and Incidence of Stroke
Arch Int Med 154:637-642, Keli,S.O.,et al, 1996
Arthritis & Anti-Inflammatory Agents as Possible Protective Factors for Alzheimer's Dis:Review of 17 Epidemiologic Studies
Neurol 47:425-432, McGeer,P.L.,et al, 1996
A Controlled Trial of Riluzole in Amyotrophic Lateral Sclerosis
NEJM 330:585-591, Bensimon,G.,et al, 1994
Growth Factors:Potential Therapeutic Applications in Neurology
JNNP 54:1445-1450, Drago,J.,et al, 1994
Evolving Toward Effective Therapy for Acute Ischemic Stroke
JAMA 270:360-364, Fisher,M.&Bogousslavsky,J., 1993
Pathophysiology of Acute Ischaemic Stroke
Lancet 339:533-536, Pulsinelli,W., 1992
The Free Radical Hypothesis in Idiopathic Parkinsonism:Evidence Against It
Ann Neurol 32:799-803, Calne,D.B., 1992
The Bioloigcal Basis for the Treatment of Acute Stroke
Neurol 41:1867-1873, Scheinberg,P., 1991